Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Equivalents (2016 - 2026)

United Therapeutics' Cash & Equivalents history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 8.25% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 8.25% decrease, with the full-year FY2025 number at $1.6 billion, down 8.25% from a year prior.
  • Cash & Equivalents hit $1.6 billion in Q4 2025 for United Therapeutics, up from $1.3 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for UTHR hit a ceiling of $1.9 billion in Q1 2025 and a floor of $795.2 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
  • Biggest five-year swings in Cash & Equivalents: decreased 15.6% in 2022 and later surged 51.81% in 2025.
  • Tracing UTHR's Cash & Equivalents over 5 years: stood at $894.8 million in 2021, then rose by 7.42% to $961.2 million in 2022, then grew by 25.65% to $1.2 billion in 2023, then skyrocketed by 40.53% to $1.7 billion in 2024, then decreased by 8.25% to $1.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for UTHR at $1.6 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.6 billion in Q2 2025.